Venomyx Therapeutics
Early Stage
EpiPen for snakebites: the antivenom of tomorrow!
Overview
Raised: $297,421
Total Commitments ($USD)
Platform
Wefunder
Start Date
03/13/2019
Close Date
07/02/2019
Min. Goal
$50,000
Max. Goal
$1,070,000
Min. Investment
$100
Security Type
SAFE
SEC Filing Type
RegCF
Valuation Cap
$4,000,000
Discount
15%
Rolling Commitments ($USD)
Status
Funded
Reporting Date
07/30/2019
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$2,679
# of Investors
506
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2015
Industry
Healthcare & Pharmaceuticals
Tech Sector
Location
La Jolla, California
Venomyx Therapeutics, with a valuation cap of $5 million, is raising crowdfunding on WeFunder. The company is developing Vipax, the world’s first broad-spectrum antivenom for snakebites. The product is ten times more effective than traditional antivenoms and much cheaper. Venomyx Therapeutics was founded by Daniel Dempsey and Deepankar Roy. The proceeds of the current crowdfunding round, with a minimum raise of $50,000, will be used to complete the preclinical trials, file an application to the FDA, and finish the research. Venomyx Therapeutics is expected to be a revolution while using biotechnology, and not animals, for the production of antivenom.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.